Protecting & sharing information | Publication of Results
14. Scientific Publications
14.1 Notwithstanding Clause 13, and in accordance with DNDi’s mission statement on providing access to the public of its research, DNDi and Entasis will encourage publications in scientific journals, abstracts or conferences of the scientific data and/or results of the Collaboration Programme pursuant to this Clause 14.
14.2 Each Party shall submit to the other Party prior to publication any draft publication relating to the Collaboration Programme for review at least twenty-eight (28) days prior to the intended date of publication, and permit it to submit comments which the publishing Party shall reasonably take into account, or object to such publication on the grounds that it discloses patentable inventions or discloses confidential technology of a Party. Should Patent Rights be sought by a Party upon any data in the draft publication, publication can be delayed by a maximum period of ninety (90) days to allow for drafting of the Patent Rights application. Each Party will, on the reasonable request from the other Party, remove from any proposed manuscript or presentation any Confidential Information of the other Party provided that neither Party will be prevented from publishing Confidential Information of the other Party (and in particular clinical data) to the extent that publication of such Confidential Information is required for any Regulatory Dossier or in order to obtain a Marketing Authorisation.
14.3 Both Parties will ensure that all written communications, including those that originate from one of their respective partners, indicate that the Drug Product was jointly developed through collaboration between DNDi and Entasis.
We are seeking additional content for the MAPGuideⓇ in the form of either full agreements or individual provisions, which may be attributed or anonymized. Please use the form below to submit an agreement or provision.
The MAPGuideⓇ is supported by the Wellcome Trust (grant numbers 219632/Z/19/Z, 221648/Z/20/Z and 225262/Z/22/Z).
If you are interested in providing funding or an in-kind contribution to support GHIAA’s work, please contact us using the form below.
Special thanks to our supporters at Duke Law SchoolCommunity Enterprise Clinic
Global Health Innovation Alliance Accelerator is a 501(c)(3) non-profit recognized by the IRS.
MAPGuideⓇ by the Global Healthcare Innovation Alliance Accelerator is licensed under CC-BY-NC-ND 4.0. To request permission for commercial or derivative use, contact firstname.lastname@example.org.
This website and the MAPGuideⓇ are provided for general informational purposes only. By using this website and any element of the MAPGuideⓇ, you agree that the information provided does not constitute legal, financial or any other form of professional advice. No relationship is created with you, nor any duty of care assumed to you, when you use this website or the MAPGuideⓇ. Neither this website nor the MAPGuide are a substitute for obtaining any legal, financial or any other form of professional advice from a suitably qualified and licensed advisor. The information provided on this website and the MAPGuideⓇ may be changed without notice and is not guaranteed to be complete, accurate, correct or up-to-date. For further information please see our Terms of Service.